Adimmune Corporation (TPE:4142)
Taiwan · Delayed Price · Currency is TWD 17.15
+0.20 (1.18%)
May 29, 2026, 1:30 PM CST
Adimmune Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,412 | 1,402 | 1,557 | 1,785 | 2,252 | 1,794 | |
Revenue Growth (YoY) | -10.95% | -9.99% | -12.78% | -20.72% | 25.52% | -4.03% |
Cost of Revenue | 1,077 | 1,113 | 1,109 | 1,374 | 1,361 | 1,177 |
Gross Profit | 335.21 | 288.49 | 448.06 | 410.94 | 891.08 | 616.86 |
Selling, General & Admin | 361.56 | 372.62 | 455.11 | 442.87 | 446.11 | 349.67 |
Research & Development | 229.52 | 237.4 | 292.05 | 296.93 | 346.42 | 321.28 |
Operating Expenses | 629.1 | 648.04 | 747.01 | 1,134 | 797.52 | 670.95 |
Operating Income | -293.89 | -359.55 | -298.95 | -722.75 | 93.57 | -54.09 |
Interest Expense | -33.05 | -31.16 | -36.49 | -33.43 | -22.59 | -14.69 |
Interest & Investment Income | 22.52 | 22.66 | 22.01 | 26.2 | 14.89 | 12.58 |
Currency Exchange Gain (Loss) | 5.2 | 5.2 | 23.58 | -31.38 | 52.62 | 4.28 |
Other Non Operating Income (Expenses) | 23.87 | 32.59 | -46.67 | -8.85 | 17.72 | 8.32 |
EBT Excluding Unusual Items | -275.34 | -330.27 | -336.51 | -770.21 | 156.21 | -43.6 |
Gain (Loss) on Sale of Investments | 0.47 | 0.47 | - | - | - | - |
Gain (Loss) on Sale of Assets | 0.02 | 0.02 | 0.02 | -0.04 | 0.01 | 0.01 |
Legal Settlements | - | - | - | - | - | -4.39 |
Other Unusual Items | - | - | 0 | 0.26 | - | 62.27 |
Pretax Income | -274.85 | -329.77 | -336.49 | -769.98 | 156.22 | 14.29 |
Income Tax Expense | - | - | - | - | 10 | - |
Earnings From Continuing Operations | -274.85 | -329.77 | -336.49 | -769.98 | 146.22 | 14.29 |
Minority Interest in Earnings | 72.67 | 89.88 | 93.74 | 130.09 | 144.76 | 28.78 |
Net Income | -202.18 | -239.89 | -242.75 | -639.89 | 290.98 | 43.07 |
Net Income to Common | -202.18 | -239.89 | -242.75 | -639.89 | 290.98 | 43.07 |
Net Income Growth | - | - | - | - | 575.65% | -96.53% |
Shares Outstanding (Basic) | 422 | 422 | 422 | 422 | 427 | 430 |
Shares Outstanding (Diluted) | 422 | 422 | 422 | 422 | 428 | 430 |
Shares Change (YoY) | 0.04% | - | - | -1.44% | -0.45% | 4.77% |
EPS (Basic) | -0.48 | -0.57 | -0.58 | -1.52 | 0.68 | 0.10 |
EPS (Diluted) | -0.48 | -0.57 | -0.58 | -1.52 | 0.68 | 0.10 |
EPS Growth | - | - | - | - | 580.00% | -96.70% |
Free Cash Flow | -197.6 | -260.61 | 437.34 | -1,270 | -711.4 | -1,325 |
Free Cash Flow Per Share | -0.47 | -0.62 | 1.04 | -3.01 | -1.66 | -3.08 |
Gross Margin | 23.75% | 20.58% | 28.78% | 23.02% | 39.57% | 34.39% |
Operating Margin | -20.82% | -25.66% | -19.20% | -40.49% | 4.16% | -3.02% |
Profit Margin | -14.32% | -17.12% | -15.59% | -35.85% | 12.92% | 2.40% |
Free Cash Flow Margin | -14.00% | -18.59% | 28.09% | -71.15% | -31.60% | -73.84% |
EBITDA | -116.73 | -180.27 | -116.2 | -528.03 | 326.68 | 150.76 |
EBITDA Margin | -8.27% | -12.86% | -7.46% | -29.58% | 14.51% | 8.40% |
D&A For EBITDA | 177.16 | 179.29 | 182.75 | 194.72 | 233.12 | 204.85 |
EBIT | -293.89 | -359.55 | -298.95 | -722.75 | 93.57 | -54.09 |
EBIT Margin | -20.82% | -25.66% | -19.20% | -40.49% | 4.16% | -3.02% |
Effective Tax Rate | - | - | - | - | 6.40% | - |